Guidance for immunization programme managers

WORKING DOCUMENT, MAY 2020
WHO TOOLKIT FOR ANALYSIS AND USE OF ROUTINE HEALTH FACILITY DATA

This document is part of the WHO *Toolkit for analysis and use of routine health facility data* – a set of capacity-building resources to optimize the analysis and use of data collected from health facilities through routine health information systems (RHIS).

The Toolkit is a collaborative effort by multiple WHO technical programmes and partners. It promotes an integrated, standards-based approach to facility data analysis, using a limited set of standardized core indicators with recommended analyses, visualizations and dashboards.

The Toolkit consists of a series of modules that can be used individually or together:

- **General principles** introduces key concepts in routine facility data analysis that are applicable to all modules.
- **Core facility indicators** is a compendium of the indicators from the various modules.
- The **Data quality review (DQR) toolkit** includes guidance and tools for systematic review of the quality of routine facility data.
- **Integrated health services analysis** targets general health service managers, providing a comprehensive, integrated analysis of tracer indicators across multiple health service components and programmes.
- The **programme-specific guidance** modules are customized according to the needs of the programme. Each module contains a guidance document, training materials and an electronic configuration package for automated dashboard production.

The materials within the Toolkit will be periodically updated and expanded.

Further details: https://www.who.int/healthinfo/tools_data_analysis_routine_facility/en/
Guidance for immunization programme managers
Contents

Acknowledgements ........................................................................ 4

Abbreviations ............................................................................. 5

Guidance overview and references .................................................. 6

1. About the data ........................................................................... 8

2. Data quality ............................................................................... 9
   2.1 Completeness and timeliness .................................................. 9
   2.2 Internal consistency ............................................................. 10
   2.3 Check for external consistency ............................................... 11

3. Core facility indicators ................................................................. 12

4. Analysis of core set of indicators .................................................. 13
   4.1 Immunization coverage for each vaccine in the national schedule 13
   4.2 Dropouts – children who start but don’t complete the immunization schedule 19
   4.3 Management of vaccine stocks ............................................. 21
   4.4 Adverse events following immunizations .................................. 24
   4.5 Immunization sessions ......................................................... 25
   4.6 Completeness of reporting ................................................... 26
Acknowledgements

This Guidance for immunization programme managers document from the Toolkit for analysis and use of routine health facility data has been developed by the World Health Organization (WHO), with the support of grants from the Bloomberg Philanthropies Data for Health Initiative; Gavi, the Vaccine Alliance; The Global Fund to Fight AIDS, Tuberculosis and Malaria; and the Norwegian Agency for Development Cooperation.

Key contributors: Jan Grevendonk, Robert Pond, Alain Poy.
Abbreviations

AEFI       adverse events following immunization
BCG        bacille Calmette-Guérin
DHIS       District Health Information Software
DHS        Demographic Health Surveys
DQR        data quality review
DTP        diphtheria–tetanus–pertussis containing vaccine
DVDMT      District Vaccination Data Management Tool
EIR        electronic immunization registry
HMIS       health management information system
HPV        human papillomavirus
MCV        measles-containing virus
MICS       Multiple Indicator Cluster Surveys
OPV        oral polio vaccine
TT or Td   tetanus-containing vaccine
WHO        World Health Organization
Guidance overview and references

Learning objectives

Immunization data should be used to support:

- operational, managerial and strategic decisions at all levels; and
- monitoring and accountability.

Those in the target audience will find this document useful as they design or improve information systems, develop training materials, evaluate the monitoring system and the data it produces, or look for ways to represent and visualize immunization data in ways that support decision-making. This document focuses on the use of routine data. Separate guidance is under development on the use of data from multiple sources (health facility surveys, population-based surveys, focused investigations in addition to the routine information system) to periodically review an immunization programme or review sector-wide progress.
Audience

This document provides guidance on the analysis and use of routine immunization data. It is aimed at:

- ministry of health decision-makers, such as immunization programme staff, data managers and health information system managers;
- immunization partner staff involved with immunization or health system strengthening; and
- consultants and staff working at research institutes involved with the assessment and improvement of immunization data and information systems.

Suggested references


Note: This document will be reviewed and updated periodically to ensure that it remains aligned with the most recent guidelines and evidence. Feedback on the document will contribute to its evolution and improvement over time.
1. About the data

Routine immunization data are recorded by staff at health facilities to track the immunization status of children and pregnant women served by the health facility, any adverse events following immunization (AEFI), vaccines and supplies used and the status of the cold chain. Summary data are periodically reported to supervisors who monitor performance indicators such as immunization coverage and vaccine wastage.

The data that are not specifically addressed in this section are those related to:

- data from immunization campaigns;
- surveillance for vaccine-preventable diseases;
- case-based data from investigation of severe AEFI; and
- financial and human resource tracking.

This guidance includes limited discussion of some closely related data:

- immunization coverage estimates from population-based surveys;
- estimates of target populations (e.g. surviving infants); and
- detailed data for immunization supply chain management.

In lower and middle-income countries, immunization data are most often collected through a monthly aggregation-based reporting system. The main exception to this basic set up occurs when electronic immunization registries (EIR) are used. In such systems, the immunization records of each person are maintained in an online electronic database, and all the data needed for monitoring can be extracted from this database, making monthly reports redundant. This section focuses on analysis and use of aggregate data, whether reported monthly or periodically extracted from an EIR.

Most lower and middle-income countries have integrated health management information systems (HMIS), used for the systematic reporting and storing of health data, including immunization data. An example of a commonly used system is the District Health Information Software version 2 (DHIS2). Additionally, in many countries, Excel-based tools are used for the reporting and analysis of immunization data. Such tools provide a systematic way to enter and store data and produce standardized visualizations. The District Vaccine Data Management Tool (DVDMT) is an example of this kind of tool. Locally stored databases have the advantage that data are always accessible, even when online access is difficult.
2. Data quality

All data have limitations that affect the reliability and interpretation of the data. The data routinely reported by health facilities are certainly no exception. The data cannot be interpreted without first knowing how complete they are and examining them for inconsistencies and errors. The data may need to be adjusted before they can be meaningfully analysed. Findings from review of data quality and explanations of any adjustments to the data must be presented explicitly and transparently as part of presentation of the analytic findings.

Whether at district or higher levels, a “data desk review” can proceed with the data immediately available to the analyst without field investigations. At national level, although a desk review can be completed with the statistics aggregated to each individual district level, a more revealing review can be carried out if the fully disaggregated data (for all facilities and all months for the period of analysis) are available.

If time and resources permit, the desk review should be complemented by a “data verification survey” of a sample of districts and health facilities to determine to what extent the reported data match with the source documents (i.e. facility registers and tally sheets) and to assess the data management system.

WHO has developed the Data quality review (DQR) toolkit to support both a desk review and field investigations of data quality. This toolkit includes an Excel-based DQR tool which, when populated with key data from health facilities and other sources, analyses the completeness, internal consistency and external consistency of the data. For countries using DHIS2 software to manage their routine data, WHO has also developed the Data Quality Tool, an application which can be installed on the national DHIS2 system that automatically generates findings from a data desk review at either national or subnational level.

The remainder of this subsection discusses the minimum data quality assessments that should be conducted as an initial step in analysis of routine immunization data.

2.1 Completeness and timeliness

Assess the completeness and timeliness of the data. Facility-level reporting completeness is defined as the number of facility reports that were received divided by the reports that were expected. District-level reporting may be complete, but do these district reports contain the reported doses from all their facilities? Timeliness is defined as the fraction of expected reports that were received before the specified deadline (e.g. the fifth business day of the following month).
Incomplete reporting reduces the number of reported doses, and thus lowers coverage indicators. It introduces a bias. If completeness is roughly the same over time then the indicator can show the trends for those facilities that reported. If, however, there is significant variation over time in completeness, then trends should be interpreted with great caution.

### 2.2 Internal consistency

Check for internal consistency. The second data quality assessment step is to look for “suspicious” reported values. Not all suspicious values are wrong. However, suspicious values merit further investigation.

**Check for outliers**

Outliers are values that differ substantially from the mean. Sometimes outliers are the result of genuine variations in programme performance, for example, as the result of an intensified effort or as the result of a stock out. However, in many cases they are clearly the result of some kind of data error. The WHO Data Quality Tool for DHIS2 automatically detects values from a health facility or from a district which are more than 3 standard deviations above or below the mean value from the same health facility or district for the same year. Charting data in a time series also provides a good visual way to find outliers.

![Chart showing trends in doses administered to detect outliers](image-url)
The peaks in the numbers of doses of Penta 1 and Penta 3 in December 2012 and August 2013 warrant investigation. Not only are they far above the usual numbers, but the number of Penta 3 also far exceeds the number of third dose oral polio vaccine (OPV3), which is normally given at the same time (an example of inconsistency between related indicators, as discussed below). This raises suspicion on the actual number of Penta doses administered. The OPV3 doses figure in January 2014 also warrants investigation.

- **Look for uniformity and patterns**: Too much uniformity in the data and the existence of patterns may also point to issues with data quality. If too many reported values are multiples of 5 or 10, this may indicate that they are guesses instead of reported values, or were obtained by counting vials, rather than tallying doses. Repeated numbers may point to mistakes. Whenever performance seems “too perfect”, it may be worth investigating further. For instance, does a district always achieve 100% coverage month after month?

- **Check for inconsistency in related indicators**: An example of such inconsistency is when there is a negative dropout over a full year between the number of children receiving the first dose of diphtheria–tetanus–pertussis containing vaccine (DTP1) and the number receiving the third dose of the vaccine. Another example, as illustrated in Fig. 2.1, is inconsistency between the number of children receiving the DTP vaccine and the number of children receiving OPV vaccine. Yet another example is when there is a negative “wastage rate” (see Section 4.3), when the number of children reported to have received a vaccine is greater than the number of doses of the vaccine reported to have been consumed.

- **Check for inconsistency between reported data and data recorded on source documents**: “Data verification” requires a survey of a representative sample of health facilities to compare the data they reported for selected months with data recorded on immunization registers or tally sheets for the same months. Such a data verification survey can provide evidence of either over-reporting or under-reporting or it can reveal problems with the recording and archiving of data. During such surveys, health staff at facility and district levels are usually interviewed to assess the adequacy of the system for data management and use.

### 2.3 Check for external consistency

Assessment of external consistency involves comparison of findings from two different data sources. Estimates of immunization coverage based upon routine data should be compared with estimates derived from population-based surveys such as Demographic Health Surveys (DHS), Multiple Indicator Cluster Surveys (MICS) or an immunization coverage survey.
## 3. Core facility indicators

<table>
<thead>
<tr>
<th>Core indicators</th>
<th>Definition</th>
<th>Disaggregation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunization coverage rate by vaccine for each vaccine in the national schedule</td>
<td>N: Number of children receiving the vaccine × 100</td>
<td>By vaccine/dose of vaccine</td>
</tr>
<tr>
<td></td>
<td>D: Estimated number of target population (e.g. infants less than 1 year)</td>
<td>Age (&lt; 1 year, ≥ 1 year for infant immunizations, ≤ 2 years, ≥ 2 years for toddler immunizations)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Status for tetanus toxoid (pregnant women, others)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Geographic region</td>
</tr>
<tr>
<td>Dropout rate for:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• DTP1 to DTP3</td>
<td>N: (DTP1 doses – DTP3 doses) × 100</td>
<td>Geographical region</td>
</tr>
<tr>
<td></td>
<td>D: DTP1 doses</td>
<td></td>
</tr>
<tr>
<td>• BCG to MCV1</td>
<td>N: (BCG doses – MCV1 doses) × 100</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D: BCG doses</td>
<td></td>
</tr>
<tr>
<td>• MCV1 to MCV2</td>
<td>N: (MCV1 – MCV2) × 100</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D: MCV1</td>
<td></td>
</tr>
<tr>
<td>Vial wastage rate (closed and open) by vaccine for each vaccine in the national schedule</td>
<td>Closed vial wastage = percentage of doses that were spoiled due to expiry, heat exposure, freezing or breakage</td>
<td>By vaccine</td>
</tr>
<tr>
<td></td>
<td>Open vial wastage = percentage of doses that were discarded after vials were opened</td>
<td>Type of spoilage</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Geographical region</td>
</tr>
<tr>
<td>Full availability of vaccines and supplies</td>
<td>Percentage of health facilities with no stock outs of any tracer vaccine or injection supply when vaccination is demanded</td>
<td>Geographical region</td>
</tr>
<tr>
<td>Functional status of cold chain equipment</td>
<td>Number of functional refrigerators</td>
<td>Geographical region</td>
</tr>
<tr>
<td>Temperature alarms</td>
<td>Number of times the temperature inside cold chain equipment exceeds or drops below a reference range</td>
<td></td>
</tr>
<tr>
<td>Serious adverse events following immunization (AEFI)</td>
<td>AEFI cases</td>
<td>Non-serious, serious</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Geographic region</td>
</tr>
<tr>
<td>Immunization session completion rate</td>
<td>N: Number of completed immunization sessions × 100</td>
<td>Outreach versus fixed</td>
</tr>
<tr>
<td></td>
<td>D: Number of planned sessions</td>
<td></td>
</tr>
</tbody>
</table>

Notes: AEFI – adverse events following immunization; BCG – bacille Calmette-Guérin; DTP – diphtheria–tetanus–pertussis containing vaccine; MCV – measles-containing virus.
4. Analysis of core set of indicators

4.1 Immunization coverage for each vaccine in the national schedule

Purpose

Immunization coverage is the fraction of a target population that is vaccinated with a defined number of doses for a certain antigen or vaccine, expressed as a percentage. Coverage is the most direct measure of programme performance and is monitored at national, subnational and facility levels in order to detect performance issues and take corrective action when needed.

Monitor vaccine doses administered and immunization coverage – analysis

Each health facility can use a cumulative coverage chart to monitor progress towards immunizing their target population.

Fig. 4.1 Example immunization coverage and target, doses
A map of last month’s BCG coverage by district shows the most recent performance with a vaccine that is ideally delivered at birth.

**Fig. 4.2** BCG coverage by district, last month

A map of last month’s Penta 3 coverage by district shows the most recent performance with a vaccine that is ideally delivered at 14 weeks of age.

**Fig. 4.3** Penta 3 coverage, last month

A map of last month’s MCV1 coverage by district shows the most recent performance with a vaccine that is ideally delivered at around 9 months of age.

**Fig. 4.4** MR1 coverage by district, last month

Ranking of districts by Penta 1 and Penta 3 coverage shows relative performance and dropout.

**Fig. 4.5** Penta 1 and Penta 3 coverage by district, last year
Doses administered by month show fluctuations in reported services as well as the consistency between related doses (e.g. DTP1 – DTP3 – OPV1 – OPV3).

Doses administered by year show trends and consistency over time without reference to targets.

Coverage by year shows progress towards targets for each dose in the immunization schedule.

For DTP3 and or MCV1, compare the routine estimate of immunization coverage nationwide to the survey estimate.
Considerations/issues for interpretation

Necessary disaggregations
Data should be disaggregated by vaccine, dose and age group of the children that received them (e.g. < 1, ≥ 1).

Monitoring access
Coverage for early doses in the immunization schedule, such as BCG or Penta 1, are indicative of access to immunization services. High first-dose coverage indicates that health services are available to a high proportion of the population and that people also accept and value vaccination.

Monitoring overall performance of immunization services
Immunization programme managers and health officials sometimes want to use routine data to monitor full immunization coverage. It is difficult to set up an aggregate reporting system that reliably reports on the number of children that are fully immunized. To do this, those aggregating the data at facility level must reliably scan all immunizations provided to the child to date to determine whether they are fully immunized.

Furthermore, with more and more vaccinations being scheduled for children and adults of older ages, defining “fully immunized” may not be straightforward. Therefore, overall performance is most often measured through the use of a tracer vaccine and dose. In many settings, the selected tracer for early infant vaccination is the third dose of DTP-containing vaccine, such as Penta 3. In countries where a first dose of measles containing vaccine (MCV1) is scheduled at the age of 9 months, MCV1 can indicate full vaccination in the first year of life, while MCV2 is often used to monitor vaccination status in the second year of life. Coverage with a last dose of human papillomavirus (HPV) vaccine indicates vaccine uptake in adolescent girls, and the vaccination status of pregnant women with a tetanus toxoid vaccine indicates the level of protection of their babies at birth.

Misclassification
When an unvaccinated or overdue child is old enough to receive a third dose of a DTP containing vaccine, sometimes health workers might erroneously register that dose as DTP3, instead of DTP1 or DTP2. This happens either because the home-based record was not available at the time of vaccination – and the health worker assumes that the child had received its previous doses – or because of a lack of correct understanding by the health worker. If this happens frequently enough, the health facility can report DTP3 greater than DTP1 (i.e. a “negative dropout rate” – discussed below), sometimes for an entire year overall.

Monitoring coverage with all vaccines in the schedule
Coverage for all other vaccines in the national schedule should also be monitored, as vaccine-specific uptake or programmatic issues may arise and need to be detected as soon as possible. After a new vaccine introduction, it is recommended to specifically monitor coverage of that vaccine to make sure it reaches levels in line with established vaccines.
Age disaggregations
To determine whether children are protected as early as possible, childhood immunization data should be disaggregated by age. In this way it is possible to monitor “timely coverage” versus “delayed coverage”. With the possible exception of the first dose of measles-containing vaccine (MCV1), timely coverage is the percentage of children immunized before 12 months of age while delayed coverage is the percentage of children immunized at 12 months or older. Some countries choose to define timely coverage with MCV1 as the percentage of children immunized before their second birthday (MCV1 < 2) rather than before their first birthday (MCV1 < 1). In either case, since MCV2 is recommended to be given between 15 and 18 months, timely coverage with MCV2 is the percentage of children immunized before their second birthday (MCV2 < 2) whereas delayed coverage is provided after their second birthday (MCV2 ≥ 2).

Unnecessary disaggregations
Sometimes the administered doses are further disaggregated, for example by the sex of the child, or the strategy that was used to vaccinate (i.e. fixed versus outreach), or whether or not the child lives within the catchment area of the health facility. These additional disaggregations are not recommended as there is scant evidence that reliable data disaggregated in these ways can be collected or meaningfully used. Moreover, the recording and reporting workload doubles every time a new level of disaggregation is introduced. Therefore, the decision to further disaggregate immunization data needs to be weighed carefully against the benefit of the use that will be made of the collected data. Those designing routine reporting forms should aim to limit the number of cells and rely upon findings from household surveys to more reliably answer many questions. The analyst can help promote streamlining of reporting forms by identifying problems with the completeness and consistency of the separate data elements and bringing such findings to the attention of those managing the health facility reporting system.

Denominators
For all vaccines in the first year of life other than birth doses (i.e. BCG, OPV0, hepatitis B vaccine 0), the target population for calculating coverage is the number of surviving infants (= live births minus infant deaths). For most countries, official census-derived population estimates are the best source of denominator data, because they are most likely established using rigorous statistical methods, and are collected independently from the health system. The use of region-specific demographic estimates of the crude birth rate and infant mortality rate, is preferable to the use of national averages. These are, however, not always available for the lowest administrative levels, and the use of uncertain or outdated population estimates is a major source of error for coverage estimation, especially at the subnational level. In some cases, local enumeration is used to estimate the size of the target population. Such an approach can provide good operational targets for health workers at local levels. However, local enumeration is not recommended for coverage monitoring at national level, as it lacks independence, and it is likely that the same children that are missed for immunization are also missed by local enumerations. Coverage in excess of 100% can either indicate an under-estimation of the denominator (which, at the level of an individual health facility or district can be in part due to mobile populations seeking services outside of their area of residence) or over-reporting of vaccines administered.
Year-to-year fluctuations in the denominator
Abrupt year-to-year increases or decreases in coverage estimates are sometimes the result of adjustments made to estimates of the target population when findings become available from a new census. To reveal the influence of such denominator adjustments, instead of graphing coverage by year (see Fig. 4.8), it is revealing to graph numerators by year (see Fig. 4.7) and denominators by year (not shown).

Options for monitoring performance when reliable denominator estimates are lacking

- Monitor trends in the absolute numbers of vaccinated children (see Fig. 4.7) rather than coverage (Fig. 4.8).
- Monitor dropout rates (see section 4.2) as they can be calculated without estimates of the target population.
- Nationwide and provincial/regional coverage can be assessed with coverage evaluation surveys.

Time series (see Figs 4.6, 4.7, 4.8)
While often showing trends in the performance of an immunization programme, time series can also be used to assess the consistency of the data. Erratic fluctuations may suggest a problem with data quality or, as just discussed, adjustments to denominator estimates. For this reason, it is useful to review the trend in doses administered (see Fig. 4.7) as well as the coverage estimates (see Fig. 4.8).

Trends
Trends must be interpreted with great caution if the reporting completeness has changed from year to year. For example, if the national completeness of facility reporting was 65% in 2015 then completeness rose to 85% in 2016, no trend should be presented unless “imputations” can be made. Imputation involves making assumptions about missing or invalid data. Such assumptions should be based upon a good understanding, after conferring with local staff, of why the data are missing or invalid (Was staffing or supply interrupted? Were staff not yet oriented to a new reporting system?) and whether the affected facilities or affected months are similar to other facilities or other months for which valid data were reported.

Comparison with survey estimates
Coverage surveys are often seen as the gold standard for coverage estimation. But while they can be very useful, it is worth pointing out that they also have inherent limitations and risks:

- **Delay in measurement**: There is typically a lag of a couple of years between when immunizations are provided and when survey estimates becomes available.

- **Limited geographic disaggregation**: Survey estimates are not commonly available for the district level, and the estimates are more uncertain even at provincial/regional levels, given the smaller sample sizes.
Quality: Not all surveys are conducted with the same quality and adherence to strict sampling and interview protocols. It is also not always easy to establish the immunization status of a child, especially if no vaccination card is available, or if the card is incompletely or incorrectly filled out, and the parent doesn’t remember all the vaccines that the child might have received. DHS and MICS surveys report the confidence intervals of survey estimates of immunization coverage. These confidence intervals estimate the effect of sampling error, which declines with sample size. However, surveys are also subject to non-sampling errors such as those due to selection bias or recall bias. The direction and size of the non-sampling error of a survey can seldom be estimated although it can well exceed the sampling error.

4.2 Dropouts – children who start but don’t complete the immunization schedule

Purpose

The dropout rates between early and later doses, for example between DTP1 and DTP3, are defined as the percentage of children that started their immunization series, but didn’t finish it for some reason. Low dropout rates are indicative of good utilization and therefore of good service quality. The MCV1 to MCV2 dropout rate assesses the ability of the programme to vaccinate beyond the first year of life.

Monitor dropout – analysis

Year-to-year trends in dropout rates.

Graphical presentation of the same dropout trends.
Considerations/issues for interpretation

Classification of districts/provinces based upon key performance indicators

Fig. 4.14 shows how districts or geographic regions can be classified based upon two key performance indicators: DTP1 coverage (< 90%, ≥ 90%, > 100%) and DTP1 to DTP3 dropout rate (< 10%, ≥ 10%, negative).
4.3 Management of vaccine stocks

Purpose

Effective supply and cold storage of vaccines is essential for good coverage and efficient use of vaccines. This subsection covers only the small subset of stock management indicators for which aggregated data can be reported monthly by each health facility.

Monitor availability of vaccines and injection supplies – analysis

![Figure 4.15](image1)

Fig. 4.15 Percentage of health facilities with “full availability” by month in last 12 months, by region

Monitor vaccine wastage – analysis

![Figure 4.16](image2)

Fig. 4.16 Closed vial wastage, by vaccine, last 12 months cumulative

![Figure 4.17](image3)

Fig. 4.17 Closed vial wastage, by vaccine for this year and last 5 years
Figure 4.18: Closed vial wastage rates for each vaccine for each month of the last 12 months.

Figure 4.19: Open vial wastage rate by vaccine by region for the last 12 months.

Figure 4.20: Open vial wastage rate by vaccine, nationwide for the this and the last 5 years.

Monitor cold chain equipment/monitor vaccine wastage – analysis

Figure 4.21: Number of high temperature alarms and number of low temperature alarms by month by region for the last 12 months.

Figure 4.22: Number of high temperature alarms and number of low temperature alarms by region for 2016.
Considerations/issues for interpretation

Monitoring for full availability
Full availability means that all immunization demands can be met. Data on unmet demand are hard to come by. How do we know with high certainty that no children were turned away because of a stock out, or that some of them only received half of the vaccines they were due to receive? It is not enough to know whether there were stocks at the end of the month. Health staff must track this continuously whenever immunizations are demanded.

Monitoring closed vial wastage
Closed vial wastage is the percentage of doses of vaccine that were spoiled during a reporting period due to expiry, heat exposure, freezing or breakage. Closed vial wastage is a good performance indicator because it can be avoided if the right management practices are in place. It is best practice to keep track of closed vial wastage by reason code, which would allow managers to identify specific shortcomings in the system. For example, unacceptably high wastage because of heat exposure, as indicated by vaccine vial monitors, would point to deficient storage or transport conditions. However, it is hard to obtain reliable wastage data by cause.

Monitoring open vial wastage

- Open vial wastage (doses used - doses administered)/doses used.
- Doses administered are the same as the number of children reported to have received the vaccine.
- Doses used = starting balance + additional doses supplied during the period - ending balance.
If the number of children reported to have received the vaccine during the period is greater than the number of doses used then the wastage rate is negative. This indicates a problem with data quality – either doses administered were over-reported or doses used were under-reported.

**Monitoring vaccine temperature alarms**
If digital temperature recorders are being used, then the number of high alarms and the number of low alarms generated by these devices over the period provide a good indication of the working status of cold chain equipment and the conditions in which vaccines are being kept.

**Monitoring the number of functional refrigerators**
The number of functional refrigerators provides a crude indication of cold chain capacity.

### 4.4 Adverse events following immunizations

**Purpose**

Adverse events following immunization (AEFI) should be monitored in two different ways:

- **Aggregate reporting systems** should be set up to monitor the total number of AEFI recorded in any health facility or district. These should be classified as either mild or severe AEFI.

- **Case reporting forms** should be filled out for all severe cases, and each of these cases should be properly investigated, including an analysis of whether the AEFI was a direct result of the vaccination or not. Serious cases are defined as those severe cases that involved hospitalization, disability or death. The investigation of a serious case can lead to the withdrawal of a vaccine batch from the market, if there is reason to believe that the vaccine was involved in causing the event.

**Monitor AEFI – analysis**

![Fig. 4.24 Non-serious and serious AEFI, by year for this and the last 5 years](image1)

![Fig. 4.25 Non-serious and serious AEFI by region for 2016](image2)
Considerations/issues for interpretation

Sensitivity of AEFI surveillance
If fewer than 10 AEFI are reported per year per 100 000 surviving infants, this could indicate that AEFI surveillance is not sufficiently sensitive.

4.5 Immunization sessions

Purpose

This indicator enables supervisors to follow up on the implementation of micro-plans. Reporting the number of sessions held versus planned can give an indication of planning, operational or budget issues at the reporting facility.

Monitor completion of planned immunization sessions – analysis

![Fig. 4.26 Non-serious and serious AEFI by region, month for the last 12 months](image)

![Fig. 4.27 Completion of planned sessions](image)
4.6 Completeness of reporting

Purpose

Complete and consistent reporting is required for routine immunization to be representative and comparable across units and over time. Understanding the trends in completeness of reporting is especially important when interpreting trends in coverage.

Monitor completeness of reporting – analysis

<table>
<thead>
<tr>
<th>October 2016</th>
<th>Trainingland</th>
</tr>
</thead>
<tbody>
<tr>
<td>![Completeness 1, last month](Fig. 4.28)</td>
<td>![Completeness 2, last 5 years](Fig. 4.29)</td>
</tr>
<tr>
<td>![Completeness 3, last 12 months](Fig. 4.30)</td>
<td></td>
</tr>
</tbody>
</table>
Considerations/issues for interpretation

Assess facility reporting completeness
District-level reporting may be complete, but do these district reports contain the reported doses from all their facilities?

Disaggregation of reporting completeness
Examine regional differences in completeness before analysing regional disparities in immunization coverage.